A mucus-dwelling gut bacterium, sold as a live or heat-treated supplement, that in early, small human studies improved insulin and cholesterol handling and limited weight regain after dieting. Consistently well tolerated, with only mild, temporary digestive effects. Benefits are modest and appear mainly in people who start with low gut levels — promising but unproven. (Full Review)

Protocol

Dose

~10 billion (10^10) cells daily

Pasteurized A. muciniphila, the trial-validated dose; once daily, no benefit from splitting.

Form

Pasteurized preferred over live

Heat-killed form matched or exceeded live in trials and has the most direct human metabolic support; live emphasizes colonization.

Timing

Once daily, with a meal

No strong data dictate timing; taken with a meal to buffer the gut and aid tolerance. Consistency matters more than the specific time.

Time to effect

Metabolic changes

~1–3 months

Insulin and cholesterol changes emerged over daily use; not within days.

Weight-maintenance effect

Over months

Reduced weight regain measured over a 24-week maintenance phase.

Benefits

Medium: Improved insulin sensitivity & glucose handling; modest improvement in blood lipids

Low: Weight-loss maintenance and modest fat reduction; reduced gut-barrier leakiness and low-grade inflammation; improved markers of liver health

Speculative: Enhanced response to cancer immunotherapy; gut-brain and mood effects; general longevity and healthy-aging effects

Contraindications

Severe immunocompromise (chemotherapy-induced neutropenia, advanced untreated HIV, post-transplant immunosuppression)

Critically ill or hospitalized patients

Central venous catheters

Pregnant or breastfeeding (untested)

Active severe inflammatory bowel disease

Key Interactions

Antibiotics

Metformin

Proton pump inhibitors (e.g., omeprazole) and osmotic laxatives

Fiber, prebiotics, and polyphenols (inulin, fructooligosaccharides, cranberry, pomegranate, grape)

Other live probiotics

Immune checkpoint inhibitors (cancer immunotherapy)

Risk & Side Effects

Medium: Mild gastrointestinal symptoms

Low: Theoretical barrier harm with overgrowth or a thin mucus layer

Speculative: Risk in severe immunocompromise or gut-barrier failure; unknown long-term and mismatched-context effects

Monitoring

Marker	Target	Why
Fasting insulin	2–5 µIU/mL	Tracks insulin sensitivity, the main human benefit
Fasting glucose	75–90 mg/dL	Core metabolic marker
HbA1c (long-term blood sugar)	< 5.4%	Captures 3-month average glucose; responsive in low-baseline diabetics
Total & LDL cholesterol	Total < 180 mg/dL; LDL context-dependent	Lipids improved modestly in the proof-of-concept trial
hs-CRP (inflammation marker)	< 1.0 mg/L	Gauges low-grade inflammation the supplement may reduce
Liver enzymes (ALT/AST)	ALT < 25 U/L; AST < 25 U/L	Liver-stress markers that improved in trials
A. muciniphila stool abundance	Mid-to-high relative abundance for age	Confirms colonization and predicts/verifies response

Cadence: Baseline, then ~3 months and 6–12 months; metabolic labs repeated annually for long-term users.

Qualitative Assessment

Digestive comfort and regularity (less bloating, more consistent stools over time)
Energy levels and post-meal energy stability
Body composition trends (waist circumference, clothing fit) over months
General sense of metabolic well-being alongside diet and exercise changes

Akkermansia muciniphila for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment